JPWO2021171002A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021171002A5 JPWO2021171002A5 JP2022550778A JP2022550778A JPWO2021171002A5 JP WO2021171002 A5 JPWO2021171002 A5 JP WO2021171002A5 JP 2022550778 A JP2022550778 A JP 2022550778A JP 2022550778 A JP2022550778 A JP 2022550778A JP WO2021171002 A5 JPWO2021171002 A5 JP WO2021171002A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- optionally
- sequence
- lcdr1
- lcdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 29
- 239000000427 antigen Substances 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 108091008874 T cell receptors Proteins 0.000 claims 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000003213 activating effect Effects 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2002581.3A GB202002581D0 (en) | 2020-02-24 | 2020-02-24 | Novel antibodies |
| GB2002581.3 | 2020-02-24 | ||
| PCT/GB2021/050459 WO2021171002A1 (en) | 2020-02-24 | 2021-02-24 | Novel antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023516925A JP2023516925A (ja) | 2023-04-21 |
| JP2023516925A5 JP2023516925A5 (https=) | 2024-02-13 |
| JPWO2021171002A5 true JPWO2021171002A5 (https=) | 2024-02-13 |
Family
ID=70108379
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550778A Pending JP2023516925A (ja) | 2020-02-24 | 2021-02-24 | 新規の抗体 |
| JP2022550813A Pending JP2023514437A (ja) | 2020-02-24 | 2021-02-24 | Ex vivoガンマデルタt細胞集団 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550813A Pending JP2023514437A (ja) | 2020-02-24 | 2021-02-24 | Ex vivoガンマデルタt細胞集団 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20230159638A1 (https=) |
| EP (3) | EP4591882A3 (https=) |
| JP (2) | JP2023516925A (https=) |
| KR (2) | KR20220145894A (https=) |
| CN (2) | CN115697401A (https=) |
| AU (2) | AU2021228266A1 (https=) |
| BR (2) | BR112022016894A2 (https=) |
| CA (2) | CA3168973A1 (https=) |
| CL (1) | CL2022002296A1 (https=) |
| CO (2) | CO2022013542A2 (https=) |
| EC (1) | ECSP22074030A (https=) |
| GB (1) | GB202002581D0 (https=) |
| IL (2) | IL295852A (https=) |
| MX (2) | MX2022010383A (https=) |
| PE (1) | PE20230438A1 (https=) |
| WO (2) | WO2021171002A1 (https=) |
| ZA (1) | ZA202209699B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202006989D0 (en) * | 2020-05-12 | 2020-06-24 | Gammadelta Therapeutics Ltd | Methods for isolating gamma delta t cells |
| AU2022222299A1 (en) | 2021-02-17 | 2023-09-07 | F-Star Therapeutics Limited | Multispecific anti-tcr delta variable 1 antibodies |
| CN119080924B (zh) * | 2024-07-04 | 2025-02-25 | 上海交通大学医学院附属第九人民医院 | 一种单克隆免疫球蛋白及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016081518A2 (en) * | 2014-11-17 | 2016-05-26 | Adicet Bio, Inc. | Engineered gamma delta t-cells |
| AU2016274633B2 (en) * | 2015-06-09 | 2022-04-21 | Gammadelta Therapeutics Ltd | Methods for the production of TCR gamma delta+ T cells |
| EP3454870A4 (en) * | 2016-05-12 | 2020-03-04 | Adicet Bio Inc. | METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF |
| GB201818243D0 (en) | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
| CA3145523A1 (en) * | 2019-08-16 | 2021-02-25 | GammaDelta Therapeutics Limited | Therapeutic uses of anti-tcr delta variable 1 antibodies |
-
2020
- 2020-02-24 GB GBGB2002581.3A patent/GB202002581D0/en not_active Ceased
-
2021
- 2021-02-24 EP EP25177102.8A patent/EP4591882A3/en active Pending
- 2021-02-24 PE PE2022001812A patent/PE20230438A1/es unknown
- 2021-02-24 WO PCT/GB2021/050459 patent/WO2021171002A1/en not_active Ceased
- 2021-02-24 AU AU2021228266A patent/AU2021228266A1/en active Pending
- 2021-02-24 WO PCT/GB2021/050460 patent/WO2021171003A1/en not_active Ceased
- 2021-02-24 JP JP2022550778A patent/JP2023516925A/ja active Pending
- 2021-02-24 AU AU2021225390A patent/AU2021225390A1/en active Pending
- 2021-02-24 KR KR1020227033455A patent/KR20220145894A/ko active Pending
- 2021-02-24 MX MX2022010383A patent/MX2022010383A/es unknown
- 2021-02-24 CN CN202180028136.1A patent/CN115697401A/zh active Pending
- 2021-02-24 CA CA3168973A patent/CA3168973A1/en active Pending
- 2021-02-24 EP EP21709757.5A patent/EP4110813A1/en active Pending
- 2021-02-24 MX MX2022010239A patent/MX2022010239A/es unknown
- 2021-02-24 KR KR1020227029501A patent/KR20220164473A/ko active Pending
- 2021-02-24 US US17/904,890 patent/US20230159638A1/en active Pending
- 2021-02-24 BR BR112022016894A patent/BR112022016894A2/pt unknown
- 2021-02-24 US US17/801,786 patent/US20230090901A1/en active Pending
- 2021-02-24 JP JP2022550813A patent/JP2023514437A/ja active Pending
- 2021-02-24 EP EP21709758.3A patent/EP4110387B1/en active Active
- 2021-02-24 BR BR112022016671A patent/BR112022016671A2/pt unknown
- 2021-02-24 CN CN202180030584.5A patent/CN115461369A/zh active Pending
- 2021-02-24 IL IL295852A patent/IL295852A/en unknown
- 2021-02-24 CA CA3172340A patent/CA3172340A1/en active Pending
- 2021-02-24 IL IL295696A patent/IL295696A/en unknown
-
2022
- 2022-08-23 CL CL2022002296A patent/CL2022002296A1/es unknown
- 2022-08-30 ZA ZA2022/09699A patent/ZA202209699B/en unknown
- 2022-09-21 CO CONC2022/0013542A patent/CO2022013542A2/es unknown
- 2022-09-22 CO CONC2022/0013633A patent/CO2022013633A2/es unknown
- 2022-09-22 EC ECSENADI202274030A patent/ECSP22074030A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2559525C2 (ru) | Белки, связывающие простагландин е2, и их применение | |
| TWI508745B (zh) | TNF-α結合蛋白 | |
| JP2020520665A5 (https=) | ||
| US20050176028A1 (en) | Deimmunized binding molecules to CD3 | |
| RU2020124623A (ru) | Антитела, специфичные к гетеродимеру cd3-дельта/эпсилон | |
| JP2021514973A5 (https=) | ||
| JP2018537962A5 (https=) | ||
| JP2018512170A5 (https=) | ||
| TW201124427A (en) | IL-1 binding proteins | |
| CN103145839A (zh) | Il-12/p40结合蛋白 | |
| JP2021500916A5 (https=) | ||
| JP2015523962A5 (https=) | ||
| JP2025183307A5 (https=) | ||
| JP2021512652A5 (https=) | ||
| JPWO2020011973A5 (https=) | ||
| JP2026026084A5 (https=) | ||
| JPWO2021171002A5 (https=) | ||
| IL277899B2 (en) | Methods and preparations for treating yellow fever | |
| JP2021533806A5 (https=) | ||
| JP2021521201A5 (https=) | ||
| WO2022023566A2 (en) | Cd-3 antibodies for the treatment of coronavirus | |
| JPWO2020257289A5 (https=) | ||
| JPWO2022079139A5 (https=) | ||
| JPWO2021171003A5 (https=) | ||
| WO2020183471A1 (en) | A method for immunosuppression |